Imaging Method Tracks Living Cells 400 Times Faster
A University of Tokyo team's label-free technique captures three-dimensional chemical images at video rates, while UC Santa Cruz researchers track psilocybin's effects on brain connections in mice.
Updated on Nov. 10, 2026 in Botany

University of Tokyo researchers developed MIP-ODT, a label-free volumetric chemical imaging technique that captures 19.2 images per second and acquires a full three-dimensional image every 52 milliseconds. Separately, UC Santa Cruz researchers observed in vivo changes in dendritic spines in mice following psilocybin administration.
Why it matters
Earlier three-dimensional mid-infrared photothermal tomography was limited to less than 0.05 images per second, restricting what researchers could observe in living systems. The psilocybin findings add direct observational evidence on how the compound alters neural connections over short timeframes.
The imaging results come from laboratory measurements of MIP-ODT speed against previous approaches, while the psilocybin findings derive from in vivo two-photon fluorescence imaging in mice. Whether the speed gains hold in more complex tissues, and how long psilocybin's effects on spine formation persist, remain open questions.
The players
University of Tokyo
A major public research university in Japan known for its work across optics, life sciences and materials research.
University of California, Santa Cruz
A public research university in California whose neuroscience researchers have studied psychedelic compounds and synaptic plasticity.
U.S. Food and Drug Administration
The federal agency responsible for regulating drugs and medical products in the United States, including the review of psychedelic therapies.
The details
MIP-ODT combines mid-infrared photothermal imaging with optical diffraction tomography, using illumination from different incident angles and a spatial light modulator to steer light and gather image data at video rates. It has been used to track lipid droplets in cultures of living cells. In the mouse study, psilocybin produced a temporary increase in new connection formation in healthy control mice, while stressed mice showed a significantly larger surge in new spine formation and halted excessive loss of existing connections.
Timeline
September 2026: The U.S. FDA hosted a public hearing on therapeutic uses of psychedelic drugs.
November 10, 2026: The imaging research article was published on optics.org.
Deeper Dive
The psilocybin observations arrive as the U.S. Food and Drug Administration weighs therapeutic uses of psychedelic drugs at its September 2026 public hearing. Mechanistic evidence on how these compounds reshape neural connections bears directly on that regulatory discussion.
Label-free imaging that runs at video rates could let researchers watch cellular processes as they happen rather than in fixed snapshots. The psilocybin work points toward how short-term changes in brain wiring could inform future drug development decisions.
The takeaway
Improvements in imaging speed can reveal biological processes that were previously invisible to researchers. Tracking how drugs reshape neural connections in real time offers a clearer basis for evaluating their effects.
Further reading
Explore more research in our Botany section.
Source note: This article includes information reported by Optics.







